Jiangsu Kanion Pharmaceutical Co.,Ltd.

Total Valuation

Jiangsu Kanion Pharmaceutical Co.,Ltd. carries a market capitalization of 6.83B, placing it among publicly traded companies globally. Its enterprise value stands at 6.34B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Jiangsu Kanion Pharmaceutical Co.,Ltd. currently has 566.16M shares outstanding.

Valuation Ratios

Jiangsu Kanion Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 30.58. The price-to-sales ratio is 2.51, and the price-to-book ratio stands at 1.76.

Enterprise Valuation

On an enterprise value basis, Jiangsu Kanion Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 22.79 and an EV/FCF ratio of 13.81. The EV/Sales ratio of 1.93 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.79 provides insight into valuation relative to core operating earnings.

Financial Position

Jiangsu Kanion Pharmaceutical Co.,Ltd. maintains a current ratio of 1.93, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 46.05 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Jiangsu Kanion Pharmaceutical Co.,Ltd. has paid -9.60M in income taxes, reflecting an effective tax rate of 51.62.

Stock Price Statistics

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s stock has declined approximately -22.72727% over the past 52 weeks. The 50-day moving average sits at 12.60, while the 200-day moving average is 14.13.

Income Statement

Over the trailing twelve months, Jiangsu Kanion Pharmaceutical Co.,Ltd. generated 3.28B in revenue and converted that into 268.81M in net income, yielding earnings per share of 0.46. EBITDA reached 278.02M, while operating income came in at 278.02M.

Balance Sheet

Jiangsu Kanion Pharmaceutical Co.,Ltd. holds 2.08B in cash and equivalents against 1.04M in total debt, resulting in a net debt position of -2.06B. Total book value stands at 4.66B, with working capital of 1.66B providing operational flexibility.

Cash Flow

After subtracting -452.42M in capital expenditures, free cash flow totaled -452.42M - equivalent to -0.81 per share.

Margins

Jiangsu Kanion Pharmaceutical Co.,Ltd. operates with a gross margin of 71.13, reflecting its pricing power and cost economics. The operating margin of 8.48 and net profit margin of 8.20 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -0.99 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Jiangsu Kanion Pharmaceutical Co.,Ltd.'s most recent stock split took place on June 24, 2016 with a 5:6 split ratio.

Scores

Jiangsu Kanion Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 4.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.